LifeCycle Pharma Receives US Patent for its MeltDose® Technology


Announcement no. 12/2007                                                        

To OMX Nordic Exchange	Hørsholm, Denmark, 15 May 2007                           



        LifeCycle Pharma Receives US Patent for its MeltDose® Technology        

Summary: LifeCycle Pharma receives US patent for its MeltDose® Technology       

LifeCycle Pharma A/S (OMX:LCP) announced today the issuance of a patent for its 
MeltDose® Technology by the US Patent and Trademark Office, US Patent No.       
7,217,431.                                                                      

The patent covers the method of making a particulate material containing a drug 
substance with low aqueous solubility, using a unique controlled agglomeration  
process.                                                                        

“The issuance of the first US patent for our MeltDose® technology marks a very  
important step in our efforts to protect the company's core technology as well  
as to protect all our product candidates which are based upon our MeltDose®     
Technology”, said Dr. Flemming Ornskov, President and CEO of LifeCycle Pharma.  
“This patent provides broad protection and gives us a potential edge over other 
companies competing in the same area” added Dr. Ornskov.                        

The issue of the MeltDose® patent does not change the company's financial       
expectations for 2007.                                                          

About MeltDose Technology:                                                      
All of LifeCycle Pharma's product candidates are based on MeltDose® technology. 
The company's MeltDose® technology has been designed to enhance the release and 
absorption of drugs in the body by incorporating the drug in a solubilized form 
in a tablet matrix, i.e. as a solid solution. By applying our MeltDose®         
technology to create new versions of existing drugs, we believe that products   
can be developed significantly faster and cheaper and with a higher success rate
compared with the development required for New Chemical Entities (“NCEs”). This 
favourable risk/reward profile is a key component of our business strategy.     




For further information please contact:                                         
LifeCycle Pharma A/S                                                            
Michael Wolff Jensen                                                            
Executive Vice President and CFO                                                
Tel. +45 40 74 62 44                                                            

                                  ---oo0oo---                                   

About LifeCycle Pharma A/S:                                                     
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging            
pharmaceutical company with a broad and late stage product pipeline in          
therapeutic areas of cholesterol management, hypertension, organ transplant and 
autoimmune diseases. LifeCycle Pharma's product candidates are proprietary and  
designed to improve the quality of existing drugs by enhancing the release and  
absorption of drugs in the human body. LifeCycle Pharma's proprietary technology
platform, MeltDose® technology, offers lower dosing, reduced side effects and   
improved safety and patient compliance, as well as reduced product development  
time and development costs. LifeCycle Pharma is listed on the OMX Nordic        
Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for      
further information about LifeCycle Pharma A/S.

Attachments

20070515-lifecycle pharma receives us patent for meltdose technology.pdf